Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41581-018-0107-2 http://scihub22266oqcxt.onion/10.1038/s41581-018-0107-2 30692664!6876298!30692664     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30692664&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Nephrol 2019 ; 15 (3): 129-143 Nephropedia Template TP {{tp|p=30692664|t=2019. C3 glomerulopathy - understanding a rare complement-driven renal disease |pdf=|usr=}}{{30692664}} gab.com Text C3 glomerulopathy - understanding a rare complement-driven renal disease JO: Nat Rev Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=30692664 #FOAvip The C3 glomerulopathies are a group of rare kidney diseases characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples. The two major subgroups of C3 glomerulopathy - dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) - have overlapping clinical and pathological features suggestive of a disease continuum. Dysregulation of the complement alternative pathway is fundamental to the manifestations of C3 glomerulopathy, although terminal pathway dysregulation is also common. Disease is driven by acquired factors in most patients - namely, autoantibodies that target the C3 or C5 convertases. These autoantibodies drive complement dysregulation by increasing the half-life of these vital but normally short-lived enzymes. Genetic variation in complement-related genes is a less frequent cause. No disease-specific treatments are available, although immunosuppressive agents and terminal complement pathway blockers are helpful in some patients. Unfortunately, no treatment is universally effective or curative. In aggregate, the limited data on renal transplantation point to a high risk of disease recurrence (both DDD and C3GN) in allograft recipients. Clinical trials are underway to test the efficacy of several first-generation drugs that target the alternative complement pathway. Twit Text FOAVip C3 glomerulopathy - understanding a rare complement-driven renal disease ????Nat Rev Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=30692664 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30692664 #FOAvip English Wikipedia <ref>{{Cite pmid|30692664}}</ref> C3 glomerulopathy - understanding a rare complement-driven renal disease #MMPMID30692664 Smith RJH; Appel GB; Blom AM; Cook HT; D'Agati VD; Fakhouri F; Fremeaux-Bacchi V; Jozsi M; Kavanagh D; Lambris JD; Noris M; Pickering MC; Remuzzi G; de Cordoba SR; Sethi S; Van der Vlag J; Zipfel PF; Nester CM Nat Rev Nephrol 2019[Mar]; 15 (3): 129-143 PMID30692664show ga The C3 glomerulopathies are a group of rare kidney diseases characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples. The two major subgroups of C3 glomerulopathy - dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) - have overlapping clinical and pathological features suggestive of a disease continuum. Dysregulation of the complement alternative pathway is fundamental to the manifestations of C3 glomerulopathy, although terminal pathway dysregulation is also common. Disease is driven by acquired factors in most patients - namely, autoantibodies that target the C3 or C5 convertases. These autoantibodies drive complement dysregulation by increasing the half-life of these vital but normally short-lived enzymes. Genetic variation in complement-related genes is a less frequent cause. No disease-specific treatments are available, although immunosuppressive agents and terminal complement pathway blockers are helpful in some patients. Unfortunately, no treatment is universally effective or curative. In aggregate, the limited data on renal transplantation point to a high risk of disease recurrence (both DDD and C3GN) in allograft recipients. Clinical trials are underway to test the efficacy of several first-generation drugs that target the alternative complement pathway. |*Autoimmunity[MESH] |Autoantibodies/immunology[MESH] |Biopsy[MESH] |Complement C3/*immunology/metabolism[MESH] |Humans[MESH] |Kidney Diseases/*immunology/metabolism[MESH] |Kidney Glomerulus/metabolism/*pathology[MESH]C3 glomerulopathy - understanding a rare complement-driven renal disea(epmc).pdf DeepDyve Pubget Overpricing